Zacks Investment Research upgraded shares of Emergent Biosolutions (NYSE:EBS) from a hold rating to a strong-buy rating in a report released on Tuesday. The firm currently has $53.00 target price on the biopharmaceutical company’s stock.

According to Zacks, “Emergent’s follow-on contract with the CDC and deals with the BARDA for BioThrax and NuThrax (next-generation anthrax vaccine) bode well for growth. We are also positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the company’s cost structure. Moreover, we are also encouraged by Emergent’s efforts to expand its manufacturing capacity to increase the production of BioThrax. Shares of the company have outperformed the broader industry in the last one year. On the flip side, the company’s sole dependence on BioThrax for its revenues is concerning. Any hiccup in the production of BioThrax could severely hamper the company’s future growth prospects. Meanwhile, Emergent faces competition from a number of companies with Biodefense products.”

Separately, Wells Fargo & Co reiterated an outperform rating and issued a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $47.67.

Emergent Biosolutions (NYSE EBS) opened at $49.08 on Tuesday. Emergent Biosolutions has a twelve month low of $27.94 and a twelve month high of $49.25. The company has a market capitalization of $1,977.87, a P/E ratio of 25.28, a P/E/G ratio of 0.92 and a beta of 1.25. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million for the quarter, compared to analysts’ expectations of $124.55 million. During the same period in the prior year, the firm posted $0.56 earnings per share. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. equities analysts anticipate that Emergent Biosolutions will post 1.58 EPS for the current fiscal year.

In other Emergent Biosolutions news, CEO Daniel Abdun-Nabi sold 21,906 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $47.91, for a total transaction of $1,049,516.46. Following the transaction, the chief executive officer now directly owns 226,040 shares in the company, valued at $10,829,576.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George A. Joulwan sold 14,251 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $41.24, for a total value of $587,711.24. Following the transaction, the director now owns 34,323 shares in the company, valued at $1,415,480.52. The disclosure for this sale can be found here. Insiders sold 206,329 shares of company stock worth $8,892,362 over the last quarter. 16.50% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the business. Insight Capital Research & Management Inc. acquired a new position in Emergent Biosolutions during the third quarter worth $1,272,000. California Public Employees Retirement System lifted its stake in Emergent Biosolutions by 5.6% during the third quarter. California Public Employees Retirement System now owns 52,276 shares of the biopharmaceutical company’s stock worth $2,115,000 after purchasing an additional 2,776 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Emergent Biosolutions during the third quarter worth $234,000. Cornerstone Capital Management Holdings LLC. lifted its stake in Emergent Biosolutions by 11.9% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 20,680 shares of the biopharmaceutical company’s stock worth $835,000 after purchasing an additional 2,200 shares in the last quarter. Finally, First Republic Investment Management Inc. lifted its stake in Emergent Biosolutions by 17.1% during the third quarter. First Republic Investment Management Inc. now owns 8,863 shares of the biopharmaceutical company’s stock worth $359,000 after purchasing an additional 1,296 shares in the last quarter. Institutional investors own 88.44% of the company’s stock.

WARNING: “Emergent Biosolutions (EBS) Upgraded by Zacks Investment Research to “Strong-Buy”” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/emergent-biosolutions-ebs-upgraded-by-zacks-investment-research-to-strong-buy/1797049.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with Analyst Ratings Network's FREE daily email newsletter.